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1. Introduction 
 
In 1980 Byers et al. [7] stated: "Because the ear is thin-skinned and has several 
anatomic subdivisions and multiple areas of lymphatic drainage, a melanoma 
developing on the ear should perhaps be considered a unique disease. Any 
correlation between the biological behaviour and certain clinical criteria...may 
not be significant for the ear."  
Few publications exist concerning malignant melanoma of the external ear 
[1;3;4;7;11;14;26;28;29]. Accordingly, there have been only few case reports 
concerning surgical strategies and SLNB for melanoma of the ear 
[6;9;10;15;16;21;26;29;30]. Almost no extensive prospective, randomized 
studies have been published concerning prognostic factors and surgical 
strategies [7;26]. 
For both functional and aesthetic reasons, smaller-than-usual excision margins 
are commonly used in treating facial melanomas [20]. Unfortunately, no 
generally accepted recommendations exist regarding excision margins or 
complete histological monitoring of surgical margins [11;21]. 
The aim of the present prospective study was to define prognostic factors for 
melanoma of the ear and to evaluate surgical strategies regarding excision 
margins, techniques of histological examination, sentinel lymph node biopsy 
(SLNB), and the prognostic relevance of tissue-conserving procedures.  
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2. Patients and Methods 
 
2.1. Patients 
161 patients (90 male/71 female) with stage I and II melanoma of the external 
ear were followed up prospectively at our clinic from 3/1976 to 3/2004 (median 
follow-up: 62 months) and were evaluated in a retrospective manner. Malignant 
melanomas of the external ear represented 3% of all stage I and II cutaneous 
melanomas and 20% of stage I and II head and neck melanomas recorded in 
the Melanoma Registry of the Department of Dermatology at the University of 
Tuebingen. The patients had given written informed consent to documentation 
and evaluation of their data stored in the Central Malignant Melanoma Registry 
of the German Dermatological Society and the Melanoma Registry of the 
Department of Dermatology at the University of Tuebingen.  
 
2.2. Diagnosis and staging 
The diagnosis of invasive (≥ level II) cutaneous melanoma was established by 
histological evaluation (haematoxylin and eosin, in some cases HMB-45 and/or 
protein S100 staining as well). Standardised initial clinical and technical 
examination was performed using chest x-ray, ultrasound of regional lymph 
nodes, ultrasound and/or computed tomography (CT) scan of the abdomen and, 
if tumour thickness exceeded 1.50 mm, cerebral CT scan. Sentinel lymph node 
biopsy (Figure 1) was performed as a standard procedure since October 1996 
in the case of tumours thicker than 1.0 mm.  
 
2.3. Surgical therapy of primary tumours 
Recommendations for excision margins varied during the observation period 
and excision margins were reduced successively (Table 1). For both functional 
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and aesthetic reasons, these recommendations could not always be followed, 
especially at the ear. The recommended excision margins were 10 - 20 mm for 
primary nodular melanoma (NM) or superficial spreading melanoma (SSM) and 
5 mm with complete three dimensional histology of excision margins (3D-
histology) for Lentigo maligna melanoma (LMM) respectively. Micrographic 
surgery, i.e. 3D-histology, was performed with a rush-fixed paraffin technique [5] 
in order to reveal subclinical tumour strands. In each case, the minimum 
excision margins were recorded (cumulatively in the case of multiple-step 
surgery). 
 
2.4. Follow-up  
As recommended by the German Dermatologic Society (DDG) [24], clinical 
follow-up examinations were scheduled every 3 months for the first five years 
after the primary excision or the first recurrence and every 6 months for the next 
5 years. Technical examinations (chest x-ray, ultrasound of the abdomen and 
regional lymph nodes) were performed at least once a year. Only those 
recurrences which occurred in the scar or in the graft of the primary excision 
were regarded as true local recurrences. True local recurrence means a 
clinically detectable regrowth of parts of the tumour which had not been 
completely excised.  
The median follow-up was 62 months. 
 
2.5. Statistical evaluation 
Statistical evaluation was performed using Version 4.0.2 of the program JMP 
(http://www.jmpdiscovery.com/).  
Survival time was computed beginning with the date of the first operation on the 
primary tumour and ending with the date of death due to melanoma or with the 
end of the prescribed observation period. Recurrence-free survival was 
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recorded as the time until first recurrence or until the end of the observation 
period. Death from other causes than melanoma and survival until the final 
follow-up examination were calculated as censored events. Survival probability 
and the probability of recurrence-free survival were calculated using the Kaplan-
Meier method. In our analysis we preferred to use ordinal or dichotomized 
parameters. For age we used the mean (59.19 years) as “breakpoint” to 
dichotomize. 
The prognostic factors were analysed for significance using the logrank test 
when proportional hazards were present and with the Wilcoxon test when 
proportional hazards were not present. 
Prognostic factors which were significant in univariate analysis were examined 
using the multivariate Cox proportional hazard model and tested for significance 
using the likelihood ratio test. Non-significant parameters were eliminated step-
by-step. In all tests a p-value of < 0.05 was regarded as statistically significant. 
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3. Results 
 
3.1. Clinical and histological risk factors 
The group studied consisted of 161 patients (stage I/II melanomas) with a 
median age of 59.9 years (22 - 88 years). The clinical and histological risk 
factors are summarized in Table 2. 
 
3.2. Surgical treatment  
Multiple-step surgery: 76.4% (n = 123) of our patients were treated with 
multiple-step surgery, for example excisional biopsy followed by definitive 
surgery with an excision margin or multiple-step 3D-histology (i.e. micrographic 
surgery) in the case of LMM. 
Excision margins ranged from 2.0 mm to 31.0 mm (median: 11 mm, mean: 
12.61 mm). 
3D-histology: Thirty-nine melanomas (24.2%) of all histological types were 
removed with 3D-histology. 3D-histology with reduced initial excision margins 
was used for 22 of 42 patients with LMM. 
Elective lymph node dissection (ELND) was performed in 5.6% (n = 9) of our 
patients from 4/1979 to 11/1991 (results: 1 positive, 8 negative). 
Sentinel lymph node biopsy (SLNB) was performed on 18.0% (n = 29) of the 
patients from 10/1996 to 3/2004 (Figure 1). Results were positive in 2 of the 29 
SLNBs (6.9%). 
Defect reconstruction: Precise data about defect reconstruction were 
documented in 146 subjects: locoregional flaps (e.g. advancement/ rotational/ 
transpositional/ pedicle flaps) were created in 34.2% (n = 50) of these patients, 
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split skin grafts in 20.5% (n = 30), primary closure in 17.8% (n = 26), wedge 
excision in 5.5% (n = 8). Partial auriculectomy or a combination of methods was 
performed in 5.5% (n = 8), full skin graft in 4.8% (n = 7), total auriculectomy in 
4.1% (n = 6) and excision with healing by secondary intention happened in 
2.1% (n = 3).  
 
3.3. Recurrence 
Recurrences appeared in 38 patients (23.6%) during the observation period. 
These are summarized in Table 3 and were mostly local recurrences (8.7%) or 
regional LN-metastases (6.2%) as a first progression of the disease. Satellite-/ 
in-transit-metastases (3.7%) appeared more often in conjunction with initial 
distant metastases (5.0%) or local recurrences (n.s.).  
In particular, preauricular lesions tended to recur. Nine of 19 preauricular 
lesions developed recurrences, 4 of these with additional distant metastases. In 
all, 23 (14.3%) patients developed distant metastases during the course of their 
follow-up. 
There were 6 preregional recurrences after negative SLNB and 1 after positive 
SLNB, but none of the patients died of melanoma-related causes after SLNB 
during the observation period. 
 
3.4. Recurrence-free survival 
The estimated recurrence-free survival rate was 83% over 3 years and 79% 
over 5 years. 
The following factors were not significant for recurrence-free survival: gender (p 
= 0.64), ulceration (present vs. absent, p = 0.50), 3D-histology (p = 0.26), and 
one step versus multiple-step surgery (p = 0.58). 
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The following risk factors were significantly correlated with recurrence-free 
survival in univariate analysis: histological tumour type (SSM, LMM, NM, others, 
p < 0.0001), level of invasion (Level II, Level III, ≥ Level IV, p < 0.0001), tumour 
thickness (≤ 1.00 mm; 1.01-2.00 mm; > 2.0 mm, p < 0.0001), excision margins 
(≤ 5 mm, 6 - 10 mm, 11 - 15 mm, > 15 mm, p = 0.035) (Figure 2), tumour 
location (front of the ear, preauricular, back of the ear, p = 0.002) (Figure 3). 
Additionally, age was a statistically significant predictor (≤ 59.19 versus > 59.19 
years, mean: 59.19 years) (p = 0.006). Patients younger than 59 years tended 
to stay free of recurrence for a longer period of time. These factors were 
evaluated in a Cox-proportional hazard model with step-by-step elimination of 
non-significant parameters. 
Tumour thickness (≤ 1.00 mm; 1.01-2.00 mm; > 2.0 mm, p < 0.0001), tumour 
location (front of the ear, preauricular, back of the ear, p = 0.011), and the 
extent of the excision margins (≤ 5 mm, 6 - 10 mm, 11 - 15 mm, > 15 mm, p = 
0.049) were independent risk factors for recurrence-free survival in multivariate 
analysis (Cox-proportional hazard model, Table 4).  
 
3.5. Disease-specific survival 
The prognosis for patients with stage I and II melanoma of the ear was relatively 
good. Fourteen of the 161 patients eventually died of melanoma-related causes. 
The survival rate was 98% over 3 years and 96% over 5 years. 
The following factors were not significant for disease-specific survival in 
univariate analysis: gender (p = 0.75), age (≤ 59.19 versus > 59.19 years, mean 
59.19 years, p = 0.13), ulceration (present vs. absent, p = 0.60), one step vs. 
multiple-step surgery (p = 0.66) and the extend of excision margins (≤ 5 mm, 6 - 
10 mm, 11 - 15 mm, > 15 mm, p = 0.95).  
Tumour thickness and invasion level according to Clark were the only significant 
risk factors for disease-specific survival in Kaplan-Meier univariate analysis 
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(respectively: p = 0.0076 for thicknesses of ≤ 1.00 mm, 1.01-2.00 mm, and > 
2.0 mm, and p = 0.0082 for Levels II, III, and IV or more (see Figure 4)).  
 
3.6. 3D-histology (i.e. Micrographic surgery) and LMM 
3D-histology with initially smaller excision margins was used to treat 22 of 42 
patients with LMM (52.4%).  
 
3.6.1. Disease-specific survival in LMM 
Of the 22 LMM patients who underwent micrographic surgery with 3D-histology, 
3 died of melanoma-related causes 25, 74 and 93 months after the initial 
diagnosis of malignant melanoma. In comparison, 2 of 20 patients who 
underwent surgery with conventional histology died of melanoma-related 
causes after 64 and 74 months, respectively.  
 
3.6.2. Recurrence-free survival in LMM 
Twenty-two of the 42 LMM patients underwent surgery with 3D-histology. Of 
these, 3 developed recurrences (1 local, 1 regional lymph node, 1 distant). The 
recurrence-free survival rate remained stable at 90.9% over 3 and 5 years of 
follow-up. Of the remaining 20 LMM patients who underwent surgery with 
conventional histology, 5 developed recurrences (1 local, 2 regional lymph 
node, 2 distant). The recurrence-free survival rate was 90% over 3 years and 
80% over 5-years (Figure 5). LMM removed surgically with 3D-histology were 
thicker (median: 0.93 mm vs. 0.83 mm), but it was possible to use reduced 
excision margins (median: 5 mm vs. 10 mm) without an increased risk of 
recurrence. 
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4. Discussion 
 
Melanoma of the external ear represent 7% to 20% [4;7;20;22;25] for melanoma 
of the head and neck and only 1% to 4% [3;4;14] for all cutaneous melanomas.  
The present group of 161 patients with melanoma of the ear is the largest such 
group studied so far. Our patients’ data were collected prospectively and were 
evaluated in a retrospective manner. During the study period the standard of 
care has changed with a tendency to narrower excision margins and since 1994 
using 3D-histology. Byers et al. [7] published an extensive study of 102 patients 
with melanoma of the ear in 1980. In that study, Byers et al. claimed that the 
localisation of ear melanomas holds particular position. More recent studies 
[4;11;12;26;30] have involved fewer patients, i.e. 2 to 78, and others have often 
included melanomas of the ear among melanomas of the head, neck, or face 
[13;20;23]. 
Surgical strategies and the prognosis for malignant melanoma of the ear have 
changed drastically in the past 20 years [1;11;26]. However, there remains little 
agreement about which treatment should be standard [1;9;11;21;26]. For 
functional and aesthetical reasons, surgeons are still searching for less invasive 
but nevertheless safe strategies with reduced excision margins and complete 
histological visualisation of excision margins (3D-histology, micrographic 
surgery) [3;17].  
 
4.1. Clinical and histological risk factors 
In contrast to our patient group other studies found a male predisposition of 
61.5% to 90.5% [1;7;11;12;21;26]. Such differences in gender-specific ratios 
can be explained by different hair-styles, habits of living and UV-exposure. 
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Locations of melanomas at the ear were similarly distributed in the present and 
previous studies, with the most frequent location at the helix and the front of the 
ear [3;4;7;26]. 
SSM represented the largest group of histological types, followed by LMM and 
NM  
Median tumour thickness in the present study was 1.08 mm, i.e. less than in 
most other studies [3;4;7;9;11;12;14;21;26;28]. 
Patients with invasion level I (in situ melanomas) were excluded from our study. 
Similarly to the literature invasion levels II and III were found in 36% [28] to 53% 
[13] and invasion levels IV and V in 40% [4] to 67% of the patients [14]. 
 
4.2. Surgical treatment 
For functional and aesthetic reasons, the recommended excision margins 
(Table 1) were often reduced in the present study (median: 11 mm). In general 
the underlying cartilage was not removed in terms of radical tumour resection. 
In some instances, for plastic reconstructive reasons, e.g. in wedge excisions, 
the cartilage was removed. The defects were covered with extended 
locoregional flaps or primary closure in 52% of our patients; partial 
auriculectomy was used for 5.5%, and total auriculectomy for 4.1%. 3D-
histology was applied in 24.2% of the cases. Multiple-step surgery ( in 76.4%) in 
general consisted either of excisional biopsy followed by re-excisions with 
additional excision margins corresponding to the tumour thickness, or of 
multiple-step surgery for LMM using 3D-histology. According to previous 
studies, multiple-step surgery with 3D-histology reduces the risk of recurrence 
of tumours with subclinical horizontal spread in regions where reduced excision 
margins have been applied for cosmetic and functional reasons [20].  
Regarding operative treatment and the radicality of methods, a marked change 
has occurred in the last 20 years. Pack et al. [25] in 1970 recommended 
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amputation in general: "...the amputation of the ear with total parotidectomy and 
radical neck dissection is the most effective plan in every case of melanoma of 
the ear...". Other authors also took this position [1;29]. 
Byers [7] first claimed that "treatment less than amputation" is sufficient. 29.4% 
(n = 30) of his patients underwent partial resection or total and peripheral 
ablation.  
Despite the cosmetic consequences, wide excision margins and less than total 
amputation were recommended by Hudson et al. [14] for functional reasons, 
especially for patients wearing spectacles. 
Wide local excision and reconstruction with chondrocutaneous flaps or a 
retroauricular advancement flap has been recommended as a useful technique 
to provide skin coverage for full-thickness ear defects and to achieve good 
cosmetic results with minimal distortion of ear shape and contour [6;21]. 
Median excision margins in the literature were 13.1 mm (median tumour 
thickness: 1.75 mm) [9], with a mean of 10 mm (n = 6: 0.5 mm, n = 8: 10 mm, n 
= 6: >10 mm) according to a report by Bono et al. [4].  
 
 
4.3. ELND and SLNB 
  
4.3.1. Elective lymph node dissection 
 
Elective lymph node dissection (ELND) was performed on 9 (5.6%) of our 
patients from 1979 to 1991. Three patients developed preregional recurrences 
after negative ELND, one after positive ELND. 
Fisher et al. [13] performed ELND on 11% of patients, Pockaj [26] on 25% 
(1985 - 2000), and Byers et al. [7] on 29% (1944 -1977). The latter author 
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suggested that neck dissection should be used only for patients with thick 
melanomas and Clark level IV or V.  
In a study of the Duke University Medical Center, Durham [13], with 82 patients, 
elective lymph node dissection significantly reduced the incidence of recurrence 
for patients with head and neck melanoma (p = 0.002). 
Until now, three prospective multicenter studies [2;8;27] have failed to 
demonstrate a beneficial effect of ELND on patients with cutaneous melanoma. 
Therefore there is only limited evidence to support the application of ELND for 
patients with melanoma of the ear. 
 
4.3.2. Sentinel lymph node biopsy 
Sentinel lymph node biopsy (SLNB) was performed on 29 (18.0%) of the 
patients in this study from 1997 to 2004 (Figure 1). Results were positive in 2 
SLNBs (6.9%). No patient died of melanoma-related causes after SLNB. Six 
preregional recurrences occurred after negative SLNB and 1 after positive 
SLNB. 
In a study by Cole [9], 9 of 19 patients underwent SLNB, with negative results in 
all cases. Of these 9, one had a recurrence.  
In a case report by Wey et al. [30], 2 patients with malignant melanoma at the 
helix had SLNB and remained permanently free of recurrences. The first was a 
primary melanoma with a thickness of 9.0 mm and Clark level III, the second 
was a 1.5 mm thick melanoma. Lymphatic drainage was preauricular in the first 
case and postauricular in the second. SLNB was negative in both cases. 
Ollila et al. [23] demonstrated that for patients with primary melanoma of the 
scalp (n = 19), auricle (n = 11), or face (n = 9), sentinel lymphadenectomy could 
be performed accurately in the parotid region and offered a low-morbidity 
alternative to routine elective superficial parotidectomy.  
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Pockaj et al. [26] perfomed SLNB in 13% (n = 10) of their patients. Within the 
median follow up of 38 months, there were no LN recurrences after SLNB. The 
authors concluded that SLNB could be used to identify patients with lymph node 
metastases who are at high risk of recurrence.  
Unfortunately, most studies [9;10;16;23;26] of SLNB for melanoma of the ear 
have dealt with small numbers of patients. Some head and neck surgeons 
argue against SLNB in the head and neck region because SLNB scars may 
complicate further surgical procedures in case of subsequent metastases. 
Our results and data from the literature do not permit definitive conclusions 
regarding a prognostic or even therapeutic impact of SLNB in patients with 
melanoma of the ear.  
 
 
4.4. Prognosis 
The prognosis for patients with stage I and II melanoma of the ear in the 
present study was good, with a survival rate of 98% over 3 years and 96% over 
5 years. In the literature, the reported 5-year survival rate varies widely, from 
31% [28] to 89% [9]. In Fisher's [13] extensive study of 5109 patients with 
melanomas of the head and neck, all 82 patients with stage II melanoma of the 
ear died within 10 years. A trend towards better prognosis during recent years is 
possibly due to early diagnosis of thinner melanomas [3;11]. Mutual neglect by 
patients and physicians of early diagnosis of ear melanomas is the main factor 
to blame for advanced melanomas, both on the ear and any other body region. 
An extensive lay education campaign addressing also barbers and hair-
dressers may improve this aspect. 
 
4.5. Recurrences 
The patients in this series had fewer recurrences (Table 3) than other groups 
studied in the literature, where recurrences reported have ranged from 31.3% 
 16 
[11] to 58% [14], with local recurrences in 8% [7] to 25% [12;14], regional lymph 
node recurrences in 17% [14] to 42% [13], and distant recurrences in 12.5% 
[12] to 17% [14]. 
 
4.6. Clinical and surgical prognostic factors  
In the present study, tumour thickness and the level of invasion were the only 
significant risk factors for overall survival in univariate analysis. They were not 
significant in the multivariate analysis. 
Tumour thickness, tumour location, and the extent of excision margins (i.e. 
reduction of excision margins below the recommended guidelines) were 
independent risk factors for recurrence-free survival in multivariate analysis 
(Figure 2, 3; Table 4). In particular, preauricular melanomas tended to recur 
locally. Preauricular lesions had a significantly higher level of invasion but did 
not differ in other prognostic parameters. 
Tumour thickness is often viewed as the most important prognostic factor for 
melanoma of the ear [3;4;7;9;11-13;26;29]. However, Hudson et al. [14] have 
called attention to the influence of the invasion level and excision margins for 
ear melanomas. In their study, 12 patients with primary melanoma of the 
external ear were treated during a 10-year period. Only two of seven patients 
with lesions > 2 mm (median 2.1 mm) survived. Six patients underwent wide-
ranging excision, and none of them developed local recurrences. However, all 6 
patients with wedge excision developed recurrences (3 local). Dost et al. [12] 
have reported that the extent of the applied resection has only a minor effect on 
recurrence and survival for this disease. 
In the large study of Byers et al. [7], tumour thickness and nodal metastases 
(42% of patients) were highly significant prognostic factors for survival. These 
results are similar to a recent study of Pockaj et al. [26], where tumour 
thickness, lymph node metastases and local recurrence significantly affected 
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systemic recurrence. Pockaj et al. [26] also wrote that excision margins ≥ 1 cm 
seemed to result in a lower rate of local recurrence. 
Even if the rate of local recurrence may rise because of narrower excision 
margins, the true local recurrences did not impair the prognosis of melanoma 
patients [19]. In that recent study [19] on melanomas of all body sites, tumour 
locality, tumour thickness and the compliance with recommended excision 
margins were independent risk factors for local recurrences. 
In the present study on ear melanomas a univariate analysis of the local-
recurrence-free survival (data not shown) showed age, locality, tumour 
thickness, histological type, level of invasion and excision margins to be 
significant risk factors for local recurrence. 
Of course we should not go back to wide excision margins. The underlying 
cartilage should not be removed in terms of radical tumour resection, but for the 
intended plastic reconstuctive procedure. Narrower excision margins had an 
effect on the incidence of local recurrence, but not on other types of recurrence. 
Excision margins have little impact on disease-specific survival. Local 
recurrence should be diagnosed early in close follow-up examinations. 
 
 
4.7. 3D-histology (i.e. Micrographic surgery) in LMM 
Twenty-two of 42 LMMs which were operated using 3D-histology (Figure 5, 6) 
were thicker compared to conventional histology, but it was possible to reduce 
excision margins without a higher rate of recurrence. 
We recommend micrographic surgery, i.e. 3D-histology, principally for LMM [5]. 
It may also be useful in other types of melanoma [18]. Nevertheless in using 
3D-histology, it seems reasonable to await a negative result of histological 
examination of excision margins before implementing more complex procedures 
to close a surgical defect on the ear. Multiple-step procedures may achieve 
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4.8. Conclusion 
• The 161 patients described here represent the largest group with 
melanoma of the ear studied so far.  
• The overall survival was related only to tumour thickness and the level of 
invasion (Clark). 
• Tumour thickness, tumour location, and the extent of excision margins 
were the most important prognostic factors for recurrence-free survival. 
• Local recurrence was more frequent with smaller excision margins, but 
there was no effect on the overall survival. Yet, we do not advocate large 
excision margins or even amputation of the external ear. Local 
recurrences should be diagnosed in follow-up examinations.  
• Smaller excision margins with 3D-histology did not exhibit an increased 
risk of local recurrence.  
• Our results do not permit conclusions regarding the prognostic impact of 
SLNB for patients with melanoma of the ear. 
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5. Summary 
 
Background: The ear's specific anatomic and lymphatic characteristics impose 
special requirements on treatment of melanoma of the ear. The aim of this 
prospective study was to define prognostic factors for melanoma of the ear and 
to evaluate surgical strategies for excision margins, histological evaluation, and 
sentinel lymph node biopsy (SLNB) in order to achieve better cosmetic and 
functional results. 
Patients and methods: 161 patients with stage I/II melanoma of the external ear 
were treated in our Department of Dermatology from 3/1976 to 3/2004 (median 
follow-up: 62 months). Malignant melanoma of the external ear represented 3% 
of the stage I/II cutaneous melanomas and 20% of the stage I/II head and neck 
melanomas recorded in the Melanoma Registry of the Department of 
Dermatology at the University of Tuebingen. Twenty of 42 Lentigo maligna 
melanomas (LMM) underwent conventional histological evaluation, 22 
underwent complete histology of three-dimensional excision margins (3D-
histology) in paraffin technique, i.e. micrographic surgery. SLNB was performed 
in 28 patients with melanomas thicker than 1.0 mm. Clinical, histological and 
surgical risk factors were evaluated by univariate and multivariate analysis. 
Results: The median thickness of the tumours in the present study was 1.08 
mm (mean: 1.51 mm; range: 0.18 - 8.50 mm), and the median excision margins 
were 11.0 mm (mean: 12.61 mm; range: 2.0 - 31.0 mm). The 3-year disease-
specific survival rate was 98%, and the 3-year recurrence-free survival rate was 
83%. Tumour thickness and the invasion level were the only risk factors 
significant for disease-specific survival. Tumour thickness, location of the 
tumour, and the extent of excision margins were independently significant risk 
factors for recurrence-free survival. LMMs removed surgically with 
accompanying 3D-histology were thicker than those examined by conventional 
histology (median: 0.93 mm vs. 0.83 mm); The use of surgery with 3D-histology, 
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i.e. micrographic surgery, made it possible to reduce the safety margins 
(median: 5 mm vs. 10 mm) without an increased risk of recurrence. Two of 29 
SLNBs were positive (6.9%). There were 6 preregional recurrences after 
negative SLNB and 1 after positive SLNB. None of the patients with a SLNB 
died of melanoma-related causes during the observation period. 
Conclusion: This is the largest series of ear melanomas reported so far. The 
overall survival depended only on the tumour thickness and level of invasion 
(Clark). Local recurrence was more frequent with smaller excision margins, but 
this did not influence the overall survival. Smaller excision margins under 3D-
histological control did not carry an increased risk of local recurrence. Our 
results do not permit conclusions regarding the prognostic impact of SLNB for 
patients with melanoma of the ear.  
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6. Figures and Tables 
 
Figure 1.  Sentinel lymph node biopsy 
Patient with a nodular melanoma on the right ear and sentinel lymph node 
biopsy. 
a.  Lymphography with peritumoral intradermal injection of blue dye 
(patent blue V) and SLNB. 
b.  Situation directly after excision of the melanoma and closure by a  
helical rim advancement flap. 
c.  Result after 6 months (the patient refused further scar correction).  
a. b. c. 
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Figure 2.  Recurrence-free survival/ excision margins                            
Recurrence-free survival in patients with melanoma of the ear (n=161) in 
relation to excision margins (coloured lines) (p=0.035). 
 
 
 
Figure 3.  Recurrence-free survival/ tumour location 
Recurrence-free survival in patients with melanoma of the ear (n=161) in 
relation to tumour location (front of the ear, preauricular, back of the ear) 
(p=0.002). 
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Figure 4.  Disease-specific survival/ tumour thickness  
Disease-specific survival in patients with melanoma of the ear (n=161) in 
relation to tumour thickness groups (< 1.00 mm; 1.01-2.00 mm; > 2.00 mm) 
(p=0.0076). 
 
 
Figure 5.  Recurrence-free survival in LMM/ 3D-histology   
Recurrence-free survival in patients with LMM melanoma of the ear (n=42) in 
relation to 3D-histology (n=22) vs. conventional histology (n=20) (p=0.045). 
Median tumour thickness 0.93 vs. 0.83 mm. 
Median excision margin 5 mm vs. 10 mm. 
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Figure 6.  3D-histology (i.e. Micrographic surgery) 
a.  LMM at the right ear of a 67-year-old patient. (tumour thickness 
1.20mm, Level IV). Tumour and safety margin are marked on the 
skin. 
 b.  Embedding of the tumour margins for 3D-histology. 
 c.  Preparation of a pediculed flap from the retroauricular region for  
 d.  reconstruction of the defect on the front of the ear. 
 e.  Result after dissection of the pediculed flap. 
 
 
 
 
 
 
 
a.                                                                                        b. 
 
 
 
 
 
 
 
 
c.                                         d.                                          e. 
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Table 1.  Excision margins recommended in Tuebingen since 1994. 
Tumour Thickness 
 
Recommendation 
(Tuebingen 1994) 
≤ 1.00 mm 10 mm 
> 1.00 mm 20 mm 
LMM 5 mm 
using 3D-histology 
 
Table 2.  Clinical and surgical parameters of 161 stage I/II patients. 
Variable 
 
  n = 161 % 
Male 90 55.9 Sex 
 Female 71 44.1 
Mean  59.19   
Median 59.90  
≤ 59.19 83 51.6 
Age (years) 
 
  
  > 59.19 78 48.4 
Front of the ear 115 71.4 
Preauricular 19 11.8 
Location 
  
  Retroauricular 27 16.8 
Unknown 2  
Mean 1.5  
Tumour thickness 
(mm) 
  
  
Median 1.1  
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≤ 1.00 77 48.4 
1.01 - 2.00 49 30.8 
  > 2.00 33 20.8 
Unknown 2   
SSM 74 46.5 
NM 35 22.0 
LMM 42 26.4 
Histological type 
  
  
  
  Other 8 5.0 
Unknown 4  
II 31 19.8 
III 52 33.1 
Level of invasion 
  
  
  ≥ IV 74 47.1 
Unknown 48  
Ulceration 14 12.4 
Histological ulceration 
  
  No ulceration 99 87.6 
One-step 38 23.6 Surgery 
  Multiple-step 123 76.4 
Unknown 17   
Mean 12.6  
Median 11.0  
≤ 5 mm 24 16.7 
6 - 10 mm 37 25.7 
Excision margins (mm) 
  
 
 
  
  
11 - 15 mm 43 29.9 
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 > 15 mm 40           24.8 
3D-histology 39 24.2 3D-histology  
(Micrographic surgery) No 3D-histology 122 75.8 
None 15   
Secondary healing 3 2.1 
Primary closure 26 17.8 
Locoregional flap 50 34.2 
Wedge excision 8 5.5 
Split skin graft 30 20.5 
Full skin graft 7 4.8 
Partial auriculectomy 8 5.5 
Total auriculectomy 6 4.1 
Defect coverage 
 
  
  
  
  
  
  
  
  
  
Combination of methods 8 5.5 
ELND 9 5.6 ELND 
(Elective Lymph Node 
Dissection) No ELND 152 94.4 
SLNB 29 18.0 SLNB 
(Sentinel Lymph Node 
Biopsy) No SLNB 132 82.0 
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Table 3.  Different types of 1st recurrence.  
First recurrence 
 
n % 
Local 14 8.7 
Satellite / in-transit 6 3.7 
Lymph node 10 6.2 
Distant 8 5.0 
Total  38 23.6 
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Table 4.  Recurrence-free survival in univariate (Kaplan-Meier) and multivariate 
(Cox-proportional hazard) analysis. 
  Univariate  Multivariate 
Variable P Relative 
risk 95% CI P 
Age 0.006    
< 59.19 years vs. > 59.19 
years     
Location 0.002   0.011 
Preauricular vs. front of the 
ear 
 4.30 1.65,10.65  
Back of the ear vs. 
preauricular  0.55 0.13, 2.06  
Tumour thickness 0.0076   < 0.0001 
1.01-2.00 mm vs. < 1.00 mm  4.79 1.71,14.97  
> 2.00 mm vs. 1.01-2.00 mm  3.67 1.47, 9.19  
Histological type < 0.0001    
SMM, LMM, NM, others     
Level of invasion < 0.0001    
II, III. IV, V     
Excision margins 0.035   0.049 
6-10 mm vs. < 5 mm  0.62 0.20, 2.10  
11-15 mm vs. 6-11 mm  1.07 0.40, 2.81  
> 15 mm vs. 11-15 mm  0.28 0.08, 0.83  
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